Rafael Villanueva-Vázquez

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

Seock‐Ah Im, Yen‐Shen Lu, Aditya Bardia et al. · New England Journal of Medicine · 2019 · 1K citations · Full text

Medicine, Oncology, Pharmacology +15

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

Debu Tripathy, Seock‐Ah Im, Marco Colleoni et al. · The Lancet Oncology · 2018 · 1K citations

Medicine, Oncology, Pharmacology +16

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im et al. · The Lancet Oncology · 2017 · 474 citations · Full text

Medicine, Oncology, Pharmacology +15

Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)

Nadia Harbeck, Fábio Franke, Rafael Villanueva-Vázquez et al. · Therapeutic Advances in Medical Oncology · 2020 · 60 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Genomic Profiling of Premenopausal HR+ and HER2– Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib

Aditya Bardia, Fei Su, Nadia Solovieff et al. · JCO Precision Oncology · 2021 · 41 citations · Full text

Medicine, Oncology, Pharmacology +17